Northern Trust’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-10,469
Closed -$7.64K 4543
2026
Q1
$7.64K Hold
10,469
﹤0.01% 4382
2025
Q4
$58.4K Buy
10,469
+6,900
+193% +$76.7K ﹤0.01% 4251
2025
Q3
$26.3K Hold
3,569
﹤0.01% 4354
2025
Q2
$27.2K Hold
3,569
﹤0.01% 4314
2025
Q1
$68.1K Buy
3,569
+737
+26% +$23.2K ﹤0.01% 4185
2024
Q4
$103K Sell
2,832
-55
-2% -$1.53K ﹤0.01% 4147
2024
Q3
$83.2K Hold
2,887
﹤0.01% 4102
2024
Q2
$73.9K Buy
2,887
+365
+14% +$16.6K ﹤0.01% 4120
2024
Q1
$191K Buy
2,522
+511
+25% +$40.5K ﹤0.01% 3912
2023
Q4
$207K Buy
2,011
+443
+28% +$39.8K ﹤0.01% 3892
2023
Q3
$153K Buy
1,568
+212
+16% +$19.8K ﹤0.01% 3905
2023
Q2
$159K Hold
1,356
﹤0.01% 3909
2023
Q1
$114K Sell
1,356
-207
-13% -$18.1K ﹤0.01% 4051
2022
Q4
$133K Buy
1,563
+1,034
+195% +$78.9K ﹤0.01% 4009
2022
Q3
$17K Hold
529
﹤0.01% 4574
2022
Q2
$12K Hold
529
﹤0.01% 4680
2022
Q1
$26K Hold
529
﹤0.01% 4642
2021
Q4
$31K Hold
529
﹤0.01% 4666
2021
Q3
$43K Hold
529
﹤0.01% 4554
2021
Q2
$51K Buy
+529
New +$53.3K ﹤0.01% 4494

Other funds holding RVPH

Northern Trust's RVPH Position: Q2 2026 in Review

Northern Trust sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q2 2026, closing a stake of 10,469 shares — an estimated $7.64K sold.

Northern Trust first reported a position in RVPH in Q2 2021 and held it in 20 quarters. The position peaked at $207K in Q4 2023. 5 funds tracked by Wall St. Rank hold RVPH as of Q2 2026.

  • Northern Trust reported no remaining REVIVA PHARMA HLDGS INC position as of Q2 2026 after selling out during the quarter.
  • Northern Trust sold 10,469 REVIVA PHARMA HLDGS INC shares in Q2 2026, an estimated $7.64K.
  • Northern Trust first reported a position in REVIVA PHARMA HLDGS INC in Q2 2021 and held it in 20 quarters.
  • Northern Trust's REVIVA PHARMA HLDGS INC position peaked at $207K in Q4 2023.
  • 5 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.